A randomised, multi-stage phase II/III study of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal cancer (the STAR trial)

Record ID 32011000720
Project Status: Ongoing
Anticipated Publish Date: 2022
Requestor: NIHR Health Technology Assessment programme
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: England, United Kingdom
MeSH Terms
  • Indoles
  • Kidney Neoplasms
  • Pyrroles
  • Sunitinib
  • Carcinoma, Renal Cell
  • Antineoplastic Agents
  • Angiogenesis Inhibitors
  • Protein Kinase Inhibitors
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
Copyright: Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.